Keep up with the latest headlines in dermatology from the past week, including a newly-developed electronic skin, the first ever use of CRISPR technology to explore the genetics of human melanin production, and more.
Researchers at Donghua University and the Shanghai Institute of Ceramics Chinese Academy of Sciences have developed an artificial, electronic skin called SPRABE, a type of E-skin produced with electrospun nanofibrous film, conductive materials, and water-based polyurethane. SPRABE allows for the acquisition of several bio signals, including electrocardiograph, electroencephalograph, and electromyograph.
A team at Stanford University recently used CRISPR technology to reveal the list of 135 melanin-promoting genes involved the process of skin pigmentation production and regulation. This is the first time CRISPR technology has been used to explore the genetics of melanin production.
New York- based dermatologist Louise Kaufmann, MD, has been awarded a grant from L'Oréal aimed at supporting her ongoing efforts to improve access to dermatologic care in rural and underserved regions of Jamaica.
A Nebraska mother is sharing the story of her son's rare skin condition, giant congenital melanocytic nevi, which affects both his skin and brain. Due to mole cells located in the brain, he suffered an in utero stroke. The condition affects approximately 20,000 babies worldwide.
Melanoma cases are on the rise in Alabama, according to the state's Department of Health. According to dermatologist Jeffrey Stricker, DO, MBA, CPE, FCAP, skin cancer incidence is increasing by upwards of 4% to 7% annually in North America.
A new study has found that heavy sun exposure not only damages skin cells but plays a role in disrupting the skin's microbiome. Significant sun exposure led to changes in microbial diversity, with notable reductions in Proteobacteria, a bacteria whose fluctuations have been linked to eczema and psoriasis.
When administering a drug used to treat heart conditions, skin cancer treatment was improved among mice in a murine model. The drug, ranolazine, may contribute to improved efficacy of currently-available melanoma therapies.